- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04944797
Crohn and Anal Incontinence (CRIA)
Prevalence, Risk Factors and Impact of Anal Incontinence in Patients Followed for Crohn's Disease
Anal incontinence affects nearly 5% of the adult population in France. It is defined as the inability for a subject to retain matter and/or gas, outside of voluntary defecation episodes. It results in an uncontrolled loss of gas or stool through the anus. To quantify, anal incontinence clinical scores have been developed of which the most used is the Cleveland score (Jorge and Wexner). A Cleveland score ≥ 5 corresponds to anal incontinence.
Crohn's disease is a chronic inflammatory disease that can affect the entire digestive tract as well as the anus. It leads to destruction of the intestinal wall if not treated early.
The presence of ano-perineal involvement is a factor of severity and poor prognosis of Crohn's disease. The management of these ano-perineal lesions is particularly difficult because of the risks of destruction of the anal sphincter and recurrence of these lesions, as well as the consequences that they induce on anal continence, sexuality and quality of life.
The prevalence of anal incontinence in Crohn's disease has been assessed in three studies by self-questionnaires. In 2013, it was studied in a cohort of British patients followed for chronic inflammatory bowel disease (IBD) (Hemorrhagic rectocolitis or Crohn's disease). Of the 3264 patients who responded to this questionnaire (32.5% of the cohort), 74% claimed to have anal incontinence and in 40% of cases it occurred regularly or a few times. In a study of 184 patients treated at an IBD expert center in Sri Lanka, anal incontinence was reported to be 26%. Only 5 patients reported regular anal incontinence. Vollebregt et al specifically studied the prevalence of anal incontinence in patients followed for Crohn's disease in a Dutch expert center. Of the 325 responses (62%), 20% of patients reported having had an episode of anal incontinence in the last 4 weeks.
In these studies, the prevalence of anal incontinence varies according to the definition of anal incontinence (qualitative or quantitative estimate) and the population studied. No French study has been published on the prevalence of anal incontinence in Crohn's disease.
Visão geral do estudo
Status
Condições
Descrição detalhada
Many risk factors for anal incontinence have been identified in the general population. In IBD, the risk factors associated with anal incontinence are gender, age, a history of anal stenosis, a history of anal fistula surgery, and a history of colorectal surgery. There is currently only one study that has identified risk factors for anal incontinence specific to Crohn's disease. In this study, the risk factors for anal incontinence were loose stools, a history of colonic or bowel resection related to Crohn's disease, a stenosing phenotype of Crohn's disease, and ano-perineal involvement in Crohn's disease.
The impact of anal incontinence on quality of life is major. Numerous trials show that this handicap is underestimated because of its shameful, embarrassing and intimate nature. The deterioration of quality of life, evaluated by the Inflammatory Bowel Disease Questionnaire (IBDQ) or Fecal Incontinence Quality-of-Life (FIQL) scores, is associated with the severity of anal incontinence in IBD. It is significantly degraded when there are several.
episodes of weekly anal incontinence in patients followed for Crohn's disease. Only one study compared the quality of life of patients with ano-perineal involvement related to Crohn's disease with that of patients with only colonic or intestinal involvement. A significant deterioration in quality of life was reported in those with anoperineal involvement related to Crohn's disease.
One of the therapeutic targets to be achieved in Crohn's disease is the "patient related outcomes" (PRO), i.e. the functional handicap secondary to the disease that is reported by the patient. Anal incontinence is one of the disabilities related to Crohn's disease. The aim of treatment is to stop the handicap and thus to improve the quality of life.
The aim of this study is to evaluate the prevalence, risk factors and impact on quality of life of anal incontinence in a French cohort of patients with Crohn's disease.
Tipo de estudo
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study will be offered to consecutively selected patients who meet the eligibility criteria. These patients will be seen in one of the two study centers (gastroenterology and proctology departments at GHPSJ or gastroenterology department at Louis Mourier Hospital):
- either in day hospital to carry out their treatment (infliximab, adalimumab, vedolizumab, ustekinumab, intravenous iron)
- or in consultation for their classic follow-up.
Descrição
Inclusion Criteria:
- Patient whose age ≥ 18 years
- French-speaking patient
- Patient followed for Crohn's disease in one of the participating centers (gastroenterology or proctology departments of the Paris-Saint Joseph Hospital Group, gastroenterology department of the Louis Mourier Hospital). The diagnosis of Crohn's disease is based on clinical, endoscopic, radiological and histological criteria.
Exclusion Criteria:
- Patient with a functional stoma
- Patient who objects to participation in the study
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under court protection
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Determine the prevalence of anal incontinence in patients with Crohn's disease at expert gastroenterology and proctology centers in France. Anal incontinence is defined by a Cleveland or Jorge and Wexner score ≥ 5
Prazo: Day 1
|
Percentage of patients with Crohn's disease with a Cleveland or Jorge and Wexner score ≥ 5
|
Day 1
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Compare the prevalence of anal incontinence in patients followed for Crohn's disease on gastroenterology services versus patients followed for ano-perineal involvement in Crohn's disease on a proctology service.
Prazo: Day 1
|
Percentages of patients followed for Crohn's disease in gastroenterology departments (Paris Saint-Joseph Hospital Group and Louis Mourier Hospital) with a Jorge and Wexner score ≥ 5 versus patients followed for ano-perineal involvement of Crohn's disease in a proctology department (Paris Saint-Joseph Hospital Group) with a Jorge and Wexner score ≥ 5
|
Day 1
|
Determine independent risk factors for anal incontinence in Crohn's disease regardless of Crohn's disease location
Prazo: Day 1
|
Analysis of risk factors for anal incontinence
|
Day 1
|
Compare the quality of life of patients with anal incontinence vs. patients without anal incontinence with Crohn's disease
Prazo: Day 1
|
Difference in medians of FIQL quality of life score in patients with anal incontinence vs. patients without anal incontinence with Crohn's disease
|
Day 1
|
Compare the quality of life of patients followed for Crohn's disease on gastroenterology services with anal incontinence versus patients followed for ano-perineal involvement of Crohn's disease on a proctology service with anal incontinence
Prazo: Day 1
|
Difference between the medians of the FIQL quality of life score in patients followed up for Crohn's disease in gastroenterology departments (Groupe hospitalier Paris Saint-Joseph and Hôpital Louis Mourier) and presenting anal incontinence compared to patients followed up for ano-perineal involvement of Crohn's disease in a proctology department (Groupe hospitalier Paris Saint-Joseph) and presenting anal incontinence
|
Day 1
|
Compare the quality of life of patients with anoperineal involvement in Crohn's disease and anal incontinence versus patients with exclusive luminal involvement in Crohn's disease and anal incontinence
Prazo: Day 1
|
Difference in medians of FIQL quality of life score in patients with anoperineal involvement of Crohn's disease and anal incontinence vs. patients with exclusive luminal involvement of Crohn's disease and anal incontinence
|
Day 1
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CRIA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Crohn
-
ProgenaBiomeRecrutamentoDoença de Crohn | Colite de Crohn | Ileocolite de Crohn | Gastrite de Crohn | Jejunite de Crohn | Duodenite de Crohn | Esofagite de Crohn | Doença de crohn | Doença de Crohn do Íleo | Ileíte de Crohn | Recaída da Doença de Crohn | Doença de Crohn agravada | Doença de Crohn em remissão | Doença de Crohn do PiloroEstados Unidos
-
Massachusetts General HospitalAmerican College of GastroenterologyAinda não está recrutandoDoenças Inflamatórias Intestinais | Doença de Crohn | Colite de Crohn | Ileocolite de Crohn | Gastrite de Crohn | Jejunite de Crohn | Duodenite de Crohn | Esofagite de CrohnEstados Unidos
-
Janssen-Cilag Ltd.RecrutamentoDoença de Crohn Fistulizante | Doença Perianal de CrohnHolanda, Estados Unidos, Bélgica, Republica da Coréia, Taiwan, Israel, Japão, Canadá, Hungria, Alemanha, Grécia, Reino Unido, Austrália, Espanha, Arábia Saudita, Polônia, Peru, Portugal, Tcheca, Itália, Jordânia, França
-
Groupe Hospitalier Paris Saint JosephConcluído
-
ViomeAtivo, não recrutandoDoença de Crohn | Colite ulcerativa | Doença de Crohn agravada | Doença de Crohn em remissão | Intestino irritávelEstados Unidos
-
University of Rome Tor VergataDesconhecidoDoença de Crohn | Ileocolite de CrohnItália
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, France; National...ConcluídoIleocolite de CrohnFrança
-
Richard Burt, MDRescindidoDOENÇA DE CROHNEstados Unidos
-
Agomab Spain S.L.RecrutamentoDoença de Crohn FibroestenóticaEstados Unidos, Itália, Polônia, Espanha, Dinamarca, Áustria, Canadá, Alemanha
-
AbbVieAtivo, não recrutandoDoença de Crohn (DC)Estados Unidos, Bélgica, Canadá, Tcheca, Dinamarca, França, Alemanha, Hungria, Israel, Itália, Holanda, Nova Zelândia, Noruega, Romênia, Espanha, Reino Unido, Polônia, Eslováquia